More on BioScrip (BIOS): Q4 easily beats across the board on a 14% rise in total sales. Gross...
More on BioScrip (BIOS): Q4 easily beats across the board on a 14% rise in total sales. Gross profit from continuing operations was 33.4% of revenue, as compared to 37.0% in the prior year period. For FY13, the company sees revenues in a range of $830M to $865M and is initially targeting 2013 Adjusted EBITDA of $67M to $73M. Analysts are forecasting revenues of $769.9M and EBITDA of $67.8M. Shares +8.3% AH.
From other sites
at CNBC.com (Oct 29, 2014)
at CNBC.com (May 27, 2014)
at CNBC.com (May 22, 2014)
at CNBC.com (Apr 10, 2014)
at CNBC.com (Apr 8, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs